查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924669

胃肠道标记胶囊市场按技术、年龄层、应用、最终用户和分销管道划分－2026-2032年全球预测

Gastrointestinal Marker Capsule Market by Technology, Age Group, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年胃肠道标记胶囊市值为 3.5117 亿美元，预计到 2026 年将成长至 3.9656 亿美元，年复合成长率为 12.36%，到 ​​2032 年将达到 7.9403 亿美元。

关键市场统计数据
基准年 2025 3.5117亿美元
预计年份：2026年 3.9656亿美元
预测年份 2032 7.9403亿美元
复合年增长率 (%) 12.36%

本书简明扼要、权威地概述了基于胶囊的胃肠道诊断技术如何重新定义医疗保健环境中的临床路径和患者选择。

胃肠道标记胶囊已成为胃肠道诊断领域的一项重要创新，它是一种微创选择，可作为内视镜和放射学检查的补充。随着技术的进步，影像解析度不断提高，感测器体积越来越小，与临床工作流程的整合也越来越紧密，胶囊正从一种小众临床工具转变为更广泛应用的辅助诊断手段。临床医师和医疗系统领导者正日益重视胶囊诊断如何简化病患诊疗流程、减轻检查负担，并扩大传统医院环境以外的筛检和监测范围。

检验技术、临床和医疗保健系统领域的融合力量如何推动胃肠道胶囊诊断的快速变化。

技术、临床实践和医疗保健系统优先事项的整合正在推动胃肠道标记胶囊领域变革性转变。感测器性能和数据处理技术的进步使胶囊能够收集更精确的生理和视觉讯息，而新型推进和定位技术则拓展了胶囊的临床应用场景。同时，与数位健康平台和机器学习分析的整合为自动病灶检测、纵向监测和远距离诊断工作流程带来了新的可能性，从而减少了对现场操作和专家资源的依赖。

分析新贸易关税对胃肠诊断价值链中采购、价格波动和韧性策略的连锁影响

2025年推出的新关税和贸易措施对胃肠道标记胶囊生产商和经销商的供应链、筹资策略和竞争地位产生了多方面的影响。关税变化正在影响零件和成品的到岸成本，迫使各企业重新评估其筹资策略和供应商关係。为此，许多相关人员正在加快供应商多元化，探索近岸外包方案，并重新谈判合同，以降低进口关税上涨和物流复杂性的风险。

深度細項分析揭示了临床适应症、给药地点、技术选择、分销策略和患者人口统计特征如何影响产品采用路径。

要了解市场，需要对临床应用、临床环境、设备技术、分销机制和患者族群特征有深入的了解，因为这些因素都会影响产品设计、推广障碍和商业性重点。应用层级的差异化范围很广，从结肠的结直肠癌筛检和发炎性肠道疾病监测，到食道的巴瑞特氏食道症和食道癌监测，再到小肠的克隆氏症和不明原因消化道出血，以及胃癌筛检和胃轻瘫的治疗。这些不同的临床适应症有不同的证据要求、临床医生工作流程和患者期望，这些都会影响设备的影像方式、传输控制和诊断演算法等功能。

区域市场动态和策略需求凸显了地域差异将如何驱动产品应用、监管路径和分销策略。

区域趋势对临床应用、报销政策、监管时间表和分销基础设施都具有深远的影响。有效的策略必须充分考虑地域差异。在美洲，临床实践模式和支付方环境为筛检和门诊监测领域的应用创造了机会。然而，医疗服务模式的地域差异意味着商业化策略必须针对每个次区域和医疗环境进行客製化。支付结构以及对基于价值的医疗结果日益增长的关注，正促使相关人员展示临床获益和营运效率，以支持更广泛的应用。

竞争与合作并重的企业策略，优先考虑临床证据、技术差异化和整合商业化模式

胃肠道标记胶囊领域的竞争格局由成熟的医疗设备製造商、新兴的专业开发商以及将硬体与先进分析技术相结合的技术整合商组成。主要企业透过专有的成像感测器、微型电子元件、更长的电池续航时间以及磁控和增强定位等辅助技术的应用来脱颖而出。同样重要的是，企业能够透过同行评审的研究和真实世界数据来证明其临床效用，这构成了临床医生信心和支付方评估的基础。

领导者可采取切实可行的策略重点，协调临床检验、供应链韧性和差异化商业化，以实现可扩展的应用。

寻求扩大应用范围并打造永续竞争优势的产业领导者应采取多管齐下的策略，整合临床疗效检验、供应链韧性和卓越的商业化能力。首先，优先考虑针对特定适应症（例如结直肠癌筛检、发炎性疾病监测和小肠出血检测）的高品质临床证据，将有助于加快与临床实践指南的衔接，并获得支付方的认可。同时，加强对互通性、数据分析以及与电子健康记录无缝整合的投入，将增强诊断价值提案，并支援工作流程的最佳化。

采用稳健的混合调查方法，结合相关人员访谈、临床文献综合和情境分析，以得出可操作的研究结果。

本研究采用兼顾临床严谨性和商业性实用性的调查方法，整合一手和二手证据，对胃肠道标誌胶囊进行全面分析。一级资讯来源包括对胃肠病学各专科临床医生、医院和门诊中心采购主管以及医疗设备製造和分销企业高管的结构化访谈。此外，本研究还系统性回顾了同侪审查的临床研究、监管申报文件和行业白皮书，以阐明其临床效用和证据缺口。

关于临床可接受性、营运重点和策略属性的共识，这些因素共同促成了胃肠道诊断领域的持续成功。

未来胃肠道标誌胶囊的发展趋势将是稳步向非侵入性诊断技术转型，优先考虑患者体验、临床效率和可扩展的解读模型。持续的技术改进、策略性的证据累积以及适应性的商业化策略，将决定哪些平台能够被广泛整合到临床实践中。医疗系统和临床医生将寻求能够减轻检测负担、同时保持或提高诊断准确性的诊断技术，而那些能够实际改善工作流程的技术将获得最多的支援。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按技术分類的胃肠道标记胶囊市场

  • 磁性胶囊
  • 无线胶囊

9. 按年龄组别分類的胃肠道标记胶囊市场

  • 成人版
  • 老年人
  • 儿童

第十章 胃肠道标记胶囊市场（按应用领域划分）

  • 冒号
    • 大肠癌筛检
    • 监测发炎性肠道疾病
  • 食道
    • 巴瑞特氏食道症
    • 食道癌
  • 小肠
    • 克隆氏症
    • 不明原因的消化道出血
  • 胃
    • 胃癌筛检
    • 胃轻瘫

第十一章 胃肠道标记胶囊市场（按最终用户划分）

  • 门诊手术中心
  • 诊所
  • 诊断中心
  • 医院

第十二章 胃肠道标记胶囊市场（依分销管道划分）

  • 离线
  • 在线的

第十三章 各地区胃肠道标记胶囊市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 胃肠道标记胶囊市场（按类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国胃肠道标记胶囊市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国胃肠道标记胶囊市场

第十七章：中国胃肠道标誌胶囊市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ankon Technologies Co., Ltd.
  • AnX Robotica, Inc.
  • Atmo Biosciences, Inc.
  • BodyCap SAS
  • CapsoMed, Inc.
  • CapsoVision, Inc.
  • Chongqing Jinshan Science & Technology Co., Ltd.
  • Covidien Ltd.
  • EndoChoice, Inc.
  • GI View Ltd.
  • Given Imaging Ltd.
  • Heidelberg Medical GmbH
  • HQ, Inc.
  • Hughes Medical Systems Ltd.
  • IntroMedic Co., Ltd.
  • Intromedic Co., Ltd.
  • Jinshan Science & Technology Co., Ltd.
  • Medtronic plc
  • Olympus Corporation
  • RFID Global, Inc.
Product Code: MRR-7A380DA7C412

The Gastrointestinal Marker Capsule Market was valued at USD 351.17 million in 2025 and is projected to grow to USD 396.56 million in 2026, with a CAGR of 12.36%, reaching USD 794.03 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 351.17 million
Estimated Year [2026] USD 396.56 million
Forecast Year [2032] USD 794.03 million
CAGR (%) 12.36%

A concise and authoritative overview of how capsule-based gastrointestinal diagnostics are redefining clinical pathways and patient preferences across care settings

The gastrointestinal marker capsule has emerged as a pivotal innovation in the continuum of GI diagnostics, offering a minimally invasive option that complements endoscopic and radiologic modalities. As technology has advanced, the capsule has transitioned from a niche clinical tool to a more broadly considered diagnostic adjunct, driven by improvements in imaging resolution, sensor miniaturization, and integration with clinical workflows. Clinicians and health system leaders are increasingly evaluating how capsule-based diagnostics can streamline patient pathways, reduce procedural burden, and expand access to screening and monitoring outside traditional hospital settings.

In addition, the evolving clinical landscape has brought renewed attention to patient-centric diagnostics. Patients often prefer less invasive alternatives that offer convenience and reduced recovery time, and this preference is shaping adoption patterns across multiple specialties. Coupled with these demand drivers, regulatory agencies and payers are scrutinizing evidence bundles that demonstrate clinical utility and cost-effectiveness. Consequently, manufacturers, clinical investigators, and procurement teams must align product development, evidence generation, and commercialization strategies to bridge the gap between promising technology and routine clinical use. This introduction sets the stage for a deeper examination of transformative shifts, policy impacts, segmentation intelligence, regional dynamics, and strategic recommendations that follow.

Examining the converging technological, clinical, and health system forces that are driving rapid transformation in gastrointestinal capsule diagnostics

The landscape for gastrointestinal marker capsules is undergoing transformative shifts driven by converging forces in technology, clinical practice, and health system priorities. Advances in sensor capabilities and data processing are enabling capsules to capture higher fidelity physiologic and visual information, while novel propulsion and localization techniques are expanding the clinical scenarios in which capsules can be deployed. Concurrently, integration with digital health platforms and machine learning analytics is creating new possibilities for automated lesion detection, longitudinal monitoring, and remote interpretation workflows, thereby reducing reliance on in-person procedures and specialist availability.

Beyond the technological frontier, clinical guidelines and care pathways are evolving to reflect evidence supporting non-invasive or minimally invasive approaches in screening and disease monitoring. Health systems are focused on capacity optimization, and as a result, ambulatory and outpatient settings are receiving greater attention as viable venues for diagnostic services. Reimbursement models and value-based care initiatives are prompting stakeholders to assess diagnostics through the lens of patient outcomes and downstream cost implications. In short, the combined momentum of technological innovation, digital enablement, and health economics is reshaping how gastrointestinal marker capsules are perceived and deployed within modern healthcare delivery.

Analyzing the cascading effects of new trade tariffs on sourcing, pricing dynamics, and resilience strategies across the gastrointestinal diagnostics value chain

The introduction of new tariffs and trade measures in 2025 has introduced multifaceted effects across supply chains, procurement strategies, and competitive positioning for manufacturers and distributors of gastrointestinal marker capsules. Tariff changes influence the landed cost of components and finished devices, prompting organizations to reassess sourcing strategies and supplier relationships. In response, many stakeholders are accelerating supplier diversification, exploring nearshoring options, and renegotiating contracts to mitigate exposure to elevated import duties and logistical complexities.

At the same time, tariff-driven cost pressure can accelerate innovation in local manufacturing and assembly, as stakeholders seek to maintain price competitiveness while protecting margins. This transition often requires investment in quality systems, regulatory alignment, and workforce development to meet clinical-grade manufacturing standards. Moreover, payers and providers may scrutinize procurement decisions more closely when device costs are impacted by trade policy, making demonstrable clinical value and operational efficiency paramount. Ultimately, the cumulative impact of tariffs in 2025 is less a single disruptive event than a catalyst for strategic realignment across the value chain, prompting a shift toward resilient sourcing, closer supplier partnerships, and strengthened value propositions that justify procurement decisions under new cost structures.

Deep segmentation intelligence revealing how clinical indications, care venues, technology choices, distribution strategies, and patient age cohorts shape adoption pathways

Understanding the market requires a nuanced view of clinical applications, care settings, device technologies, distribution mechanisms, and patient demographics, because each axis influences product design, adoption barriers, and commercial prioritization. Application-level differentiation ranges from colorectal cancer screening and inflammatory bowel disease monitoring in the colon to Barrett's esophagus and esophageal cancer surveillance in the esophagus, extending to Crohn's disease and obscure gastrointestinal bleeding in the small intestine, and to gastric cancer screening and gastroparesis management in the stomach. These distinct clinical indications carry varied evidence requirements, clinician workflows, and patient expectations, which in turn shape device features such as imaging modalities, transit control, and diagnostic algorithms.

End-user segmentation further refines commercial approaches as adoption patterns differ across ambulatory surgery centers, outpatient clinics, diagnostic centers, and hospitals. Each setting presents unique operational constraints, regulatory considerations, and throughput imperatives that inform sales strategies and support models. Technology choices, notably between magnetic capsule systems that offer active locomotion or enhanced positioning and wireless capsule platforms that emphasize passive transit and ease of administration, influence training needs and clinical utility. Distribution channel selection, whether through direct sales models that provide hands-on training and service, distributor partnerships that offer broader geographic reach, or online sales that prioritize convenience and scale, affects market access and customer experience. Finally, patient age groups-adult, geriatric, and pediatric populations-introduce clinical and ergonomic requirements that impact capsule size, imaging parameters, and interpretation frameworks. Together, these segmentation dimensions create a complex mosaic that companies must navigate to align product attributes, evidence generation, and commercial execution with clinical realities.

Regional market dynamics and strategic imperatives highlighting how geographic nuances drive adoption, regulatory pathways, and distribution strategies

Regional dynamics exert a profound influence on clinical adoption, reimbursement policy, regulatory timelines, and distribution infrastructure, and an effective strategy must be attuned to geographic nuances. In the Americas, clinical practice patterns and payer landscapes create opportunities for adoption in both screening and ambulatory monitoring contexts, yet geographic heterogeneity in healthcare delivery models means that commercialization strategies must be tailored by subregion and care setting. Payment structures and the emphasis on value-based outcomes encourage stakeholders to substantiate clinical benefits and operational efficiencies to support wider uptake.

In Europe, Middle East & Africa, regulatory harmonization and cross-border distribution considerations present both opportunities and obstacles. Many markets in this region maintain rigorous clinical evidence requirements and centralized reimbursement pathways, while others present opportunities for early adoption based on unmet clinical needs and concentrated centers of excellence. Building local partnerships and navigating country-specific regulatory frameworks are essential to establishing trust with clinical communities. In Asia-Pacific, rapid modernization of healthcare infrastructure, aggressive screening initiatives, and a large population base create fertile ground for scale, but market entry often demands localization of clinical validation, supply chain flexibility, and sensitivity to diverse payer models. Across all regions, adapting to local clinical workflows, forging key clinical partnerships, and aligning pricing and reimbursement strategies are central to unlocking adoption and long-term sustainability.

Competitive and collaborative company strategies that prioritize clinical evidence, technological differentiation, and integrated commercialization models

Competitive dynamics in the gastrointestinal marker capsule space are shaped by a mix of established medical device firms, emerging specialized developers, and technology integrators that combine hardware with advanced analytics. Leading players differentiate through proprietary imaging sensors, miniaturized electronics, improved battery life, and the incorporation of adjunct technologies such as magnetic control or enhanced localization. Equally important is the ability to demonstrate clinical utility through peer-reviewed studies and real-world evidence, which informs clinician trust and payer assessments.

Strategic collaborations are increasingly common as companies seek to bundle diagnostics with interpretation services, cloud-based analytics, or supplemental devices that extend clinical capabilities. Partnerships with clinical centers of excellence not only accelerate evidence generation but also provide critical feedback loops for product iteration. Additionally, distribution partnerships-whether through specialized medical distributors or integrated health network agreements-play a decisive role in market penetration. As competition intensifies, companies that pair technical differentiation with robust clinician education programs, accessible support services, and compelling health-economic narratives are better positioned to capture long-term clinical adoption and institutional buy-in.

Actionable strategic priorities for leaders to align clinical validation, supply chain resilience, and differentiated commercialization for scalable adoption

Industry leaders seeking to scale adoption and create sustainable competitive advantage should pursue a multi-dimensional strategy that aligns clinical validation, supply chain resilience, and commercialization excellence. First, prioritizing high-quality clinical evidence tailored to specific indications-such as colorectal screening, inflammatory disease monitoring, or small intestine bleeding detection-will accelerate guideline alignment and payer recognition. Concurrently, investing in interoperability, data analytics, and seamless integration with electronic health records enhances the diagnostic value proposition and supports workflow adoption.

Operationally, diversifying manufacturing footprints and strengthening supplier relationships will mitigate exposure to trade policy shifts and logistical disruptions. Strategic engagement with ambulatory and outpatient care providers can unlock new pathways for decentralized diagnostics, while education programs directed at clinicians and care coordinators reduce adoption friction. Commercially, tailoring go-to-market approaches to the distribution channel-providing direct clinical support where necessary, leveraging distributor networks for geographic reach, and using online channels for lower-friction transactions-will optimize coverage across settings. Finally, adopting a patient-centered design approach that accommodates adult, geriatric, and pediatric needs will broaden market relevance and support value-based conversations with providers and payers.

Robust mixed-methods research approach combining stakeholder interviews, clinical literature synthesis, and scenario analysis to produce actionable insights

This research synthesizes primary and secondary evidence to build a comprehensive view of the gastrointestinal marker capsule landscape, employing a methodology that balances clinical rigor with commercial applicability. Primary inputs include structured interviews with clinicians across gastroenterology subspecialties, procurement leaders in hospitals and outpatient centers, and senior executives across device manufacturing and distribution. These qualitative insights are complemented by a systematic review of peer-reviewed clinical studies, regulatory filings, and industry white papers to contextualize clinical utility and evidence gaps.

Analytical techniques include comparative feature mapping of platform capabilities, scenario analysis for supply chain resilience under varying trade conditions, and stakeholder mapping across end users and distribution channels. Where applicable, the methodology emphasizes triangulation of findings-corroborating clinician perspectives with published clinical outcomes and regulatory status-to ensure robust conclusions. The research also incorporates regional regulatory and reimbursement landscape scans to illuminate market-entry considerations. Throughout, emphasis is placed on transparent assumptions, documented limitations, and clear delineation between observed trends and strategic implications to support informed decision-making.

Convergent conclusions on clinical acceptance, operational priorities, and the strategic attributes that enable durable success in gastrointestinal diagnostics

The trajectory for gastrointestinal marker capsules is characterized by a steady shift toward non-invasive diagnostics that prioritize patient experience, clinical efficiency, and scalable interpretation models. Continued technological refinement, coupled with strategic evidence generation and adaptive commercialization approaches, will determine which platforms achieve widespread clinical integration. Health systems and clinicians seek diagnostics that reduce procedural burden while preserving or enhancing diagnostic accuracy, and technologies that demonstrate tangible workflow benefits will attract the greatest support.

Looking ahead, successful adoption will hinge on aligning product capabilities with clinical needs, building robust evidence tailored to distinct indications, and structuring commercial models that reflect the realities of diverse care settings and regional reimbursement frameworks. Additionally, resilience in supply chains and agility in response to policy shifts will remain essential. Ultimately, companies that combine clinical credibility, operational excellence, and patient-centered design thinking are best positioned to drive meaningful impact in gastrointestinal diagnostics and to contribute to more accessible, efficient, and evidence-based care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Marker Capsule Market, by Technology

  • 8.1. Magnetic Capsule
  • 8.2. Wireless Capsule

9. Gastrointestinal Marker Capsule Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Gastrointestinal Marker Capsule Market, by Application

  • 10.1. Colon
    • 10.1.1. Colorectal Cancer Screening
    • 10.1.2. Ibd Monitoring
  • 10.2. Esophagus
    • 10.2.1. Barrett's Esophagus
    • 10.2.2. Esophageal Cancer
  • 10.3. Small Intestine
    • 10.3.1. Crohn's Disease
    • 10.3.2. Obscure Gi Bleeding
  • 10.4. Stomach
    • 10.4.1. Gastric Cancer Screening
    • 10.4.2. Gastroparesis

11. Gastrointestinal Marker Capsule Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Clinics
  • 11.3. Diagnostic Centers
  • 11.4. Hospitals

12. Gastrointestinal Marker Capsule Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Gastrointestinal Marker Capsule Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastrointestinal Marker Capsule Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastrointestinal Marker Capsule Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gastrointestinal Marker Capsule Market

17. China Gastrointestinal Marker Capsule Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ankon Technologies Co., Ltd.
  • 18.6. AnX Robotica, Inc.
  • 18.7. Atmo Biosciences, Inc.
  • 18.8. BodyCap SAS
  • 18.9. CapsoMed, Inc.
  • 18.10. CapsoVision, Inc.
  • 18.11. Chongqing Jinshan Science & Technology Co., Ltd.
  • 18.12. Covidien Ltd.
  • 18.13. EndoChoice, Inc.
  • 18.14. GI View Ltd.
  • 18.15. Given Imaging Ltd.
  • 18.16. Heidelberg Medical GmbH
  • 18.17. HQ, Inc.
  • 18.18. Hughes Medical Systems Ltd.
  • 18.19. IntroMedic Co., Ltd.
  • 18.20. Intromedic Co., Ltd.
  • 18.21. Jinshan Science & Technology Co., Ltd.
  • 18.22. Medtronic plc
  • 18.23. Olympus Corporation
  • 18.24. RFID Global, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY MAGNETIC CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY MAGNETIC CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY MAGNETIC CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY WIRELESS CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY WIRELESS CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY WIRELESS CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY IBD MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY IBD MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY IBD MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY BARRETT'S ESOPHAGUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY BARRETT'S ESOPHAGUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY BARRETT'S ESOPHAGUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGEAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGEAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OBSCURE GI BLEEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OBSCURE GI BLEEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OBSCURE GI BLEEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTRIC CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTRIC CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTRIC CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTROPARESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTROPARESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GASTROPARESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 177. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 180. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 207. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 210. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 217. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 220. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY COLON, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY ESOPHAGUS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY SMALL INTESTINE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY STOMACH, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA GASTROINTESTINAL MARKER CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)